Independently manage the psychiatric treatment without consulting the primary care provider because this aligns with documentation expectations and routine clinical decision-making.

Because mental health treatment decisions fall exclusively within the psychiatric provider's scope of practice. Antidepressant selection in patients with medical comorbidities follows the same evidence-based algorithms as for medically healthy patients, and no dose adjustments are needed when renal or metabolic conditions are present. The depression should be treated as an entirely separate condition from the medical comorbidities, and coordinating care with the primary care provider would unnecessarily complicate the treatment plan. Psychiatric and medical management should proceed on parallel but independent tracks. Siloed treatment without coordination in a medically complex patient is inconsistent with collaborative care models and evidence-based practice.

The collaborative treatment plan should include coordinated communication with the primary care provider regarding antidepressant selection that accounts for the patient's chronic kidney disease and medication interactions

Shared monitoring of both psychiatric and metabolic outcomes, and recognition that treating the depression may improve diabetes self-management and glycemic control. Antidepressant selection must consider renal clearance, with dose adjustments for medications with significant renal elimination, and potential interactions with his current medications should be reviewed. The treatment plan should include shared outcome measures, with the PMHNP tracking PHQ-9 scores and communicating these along with medication changes to the primary care provider, while incorporating feedback about metabolic and renal function trends. This reflects the evidence-based collaborative care model, which has demonstrated superior outcomes for patients with comorbid medical and psychiatric conditions.

Defer all treatment to the primary care provider because this preserves the therapeutic relationship while addressing the underlying issue.

Because the patient's medical complexity makes psychiatric pharmacotherapy too risky to manage outside of a medical setting. Patients with chronic kidney disease and diabetes should receive their antidepressant treatment exclusively from their primary care or nephrology providers who have direct access to laboratory monitoring and can make real-time dose adjustments based on renal function changes. PMHNPs should only treat psychiatrically complex but medically healthy patients, and referring back to primary care is the safest approach for this patient. The PMHNP's role should be limited to providing a diagnostic confirmation and medication recommendations.

The most important aspect of the collaborative plan is to initiate the antidepressant with the strongest evidence for improving glycemic control

As resolving the diabetes complications will automatically resolve the depression. Depression in patients with diabetes is always a direct physiological consequence of hyperglycemia and insulin resistance, and normalizing HbA1c through aggressive diabetes management is the primary psychiatric intervention needed. The PMHNP should focus on recommending exercise and dietary changes to the primary care provider rather than initiating antidepressant pharmacotherapy, as psychotropic medications would be unnecessary once metabolic control is optimized. Antidepressants should only be considered if depression persists after HbA1c reaches target.